Lantern Pharma to Showcase AI Co-Scientist Platform withZeta.ai in Live Public Demo
Lantern Pharma will host its first live demonstration of the withZeta.ai AI co-scientist platform on April 30, 2026, showcasing its ability to accelerate oncology drug discovery and marking a potential new revenue stream through a subscription model.
Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event, led by CEO Panna Sharma, will feature a real-time, interactive demonstration of the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets.
According to the company, the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model. This demonstration is a significant step for Lantern as it moves toward commercializing its AI capabilities beyond internal drug development. The withZeta.ai platform is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company.
The announcement underscores a broader trend in the biotech industry: the integration of artificial intelligence to streamline drug development. Lantern’s platform aims to reduce the time and cost associated with bringing new cancer therapies to market. The company has a clinical pipeline that includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Lantern’s AI capabilities are built on its proprietary RADR platform, which leverages machine learning to analyze large datasets. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The live demo will provide potential subscribers and investors with a firsthand look at the platform’s ability to integrate diverse datasets and execute complex research tasks.
The event is expected to draw interest from the pharmaceutical and investment communities, as AI-driven drug discovery platforms are gaining traction as a way to address the high failure rates and long timelines in oncology drug development. For more details, the full press release is available at https://ibn.fm/wzevl. Latest news and updates regarding Lantern Pharma can be accessed at the company’s newsroom at https://ibn.fm/LTRN.